CTLA4 and melanoma: Currently, PD-1 and CTLA-4 are the therapeutic targets against malignant melanoma, and anti-PD-1 antibody (nivolumab) and anti-CTLA-4 antibody (ipilimumab) are currently used as single-agent or combination therapies for advanced or recurrent cases, as well as adjuvant therapy after surgery.